Global Biopolar Disorder Therapeutics Market 2015-2019

Global Biopolar Disorder Therapeutics Market 2015-2019

Category : Healthcare
Published On : December  2015
Pages : 94



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About bipolar disorder therapeutics
Bipolar disorder is a psychological disorder characterized by intermittent mood swings. The individual suffering with this disorder experiences extreme poles of either mania or depression or both. The disorder severely affects the personal, social, and professional life of an individual. The symptoms usually include drastic changes in mood, either as a manic episode or a depressive episode. There is no complete cure for the disorder. Atypical antipsychotics, mood stabilizers, and antidepressants are being widely used in for treatment. It is considered as a lifelong disease and the discontinuation of the medication can lead to relapse of the condition.

Technavios analysts forecast the global bipolar disorder therapeutics market to grow at a CAGR of 2.24% over the period 2014-2019.

Covered in this report
The report covers the present scenario and growth prospects of the global bipolar disorder therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of bipolar disorder.

Technavios report, Global Bipolar Disorder Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global bipolar disorder therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
• Americas
• APAC
• EMEA

Key vendors
• Allergan
• AstraZeneca
• BMS
• Eli Lilly
• GlaxoSmithKline
• Janssen Pharmaceuticals 

Other prominent vendors
• AbbVie
• Abital Pharma
• Astellas
• Convergence Pharmaceuticals
• D Pharm
• Delpor
• Gedeon Richter
• H. Lundbeck
• Intra-Cellular Therapies
• Novartis
• Noven Pharmaceuticals
• Omeros Corporation
• Otsuka
• Pfizer
• PNBDevCo
• Reviva Pharmaceuticals 
• SK Biopharmaceuticals
• Sunovion Pharmaceutical 

Key market driver
• Increase in prevalence of bipolar disorder
• For a full, detailed list, view our report

Key market challenge
• Use of alternative therapies
• For a full, detailed list, view our report

Key market trend
• Rise in public awareness
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Understanding the disorder
Types of bipolar disorder
Causes
Signs and symptoms
Management
Self-help
Epidemiology

PART 06: Pipeline analysis
ITI-007
FK949E
PROCYCLOX
RP5603
CNV1061436
LY2979165
DP-VPA
SKL-PSY
PGW-5
DLP-114
DLP-115
Small molecule targeting GPR78

PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08: Market segmentation by drug class
Mood stabilizers
Anticonvulsants
Atypical antipsychotics
Antidepressant drugs
Anti-anxiety drugs

PART 09: Market segmentation by mechanism of action
Selective serotonin reuptake inhibitors
Serotonin-norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Benzodiazepines
Beta blockers
Others

PART 10: Geographical segmentation
Global bipolar disorder therapeutics market by geographical segmentation 2014-2019
Bipolar disorder therapeutics market in Americas
Bipolar disorder therapeutics market in EMEA
Bipolar disorder therapeutics market in APAC

PART 11: Market drivers
Increase in prevalence of bipolar disorder
High unmet need
Increase in R&D

PART 12: Impact of drivers

PART 13: Market challenges
Use of alternative therapies
Lack of availability of standard diagnostic methods
Limited awareness of disease
Increase in patent expiries

PART 14: Impact of drivers and challenges

PART 15: Market trends
Rise in public awareness
Patient assistance programs
Strategic alliances

PART 16: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 17: Key vendor analysis
Allergan
AstraZeneca
BMS
Eli Lilly
GSK
Janssen Pharmaceuticals

PART 18: Appendix
List of abbreviatios

PART 19: Explore Technavio

Exhibit 01: Product offerings
Exhibit 02: Signs and symptoms of bipolar disorder
Exhibit 03: Signs and symptoms of mania
Exhibit 04: Signs and symptoms of depression
Exhibit 05: Treatment options for bipolar disorder
Exhibit 06: Medications for treating bipolar disorder
Exhibit 07: Global bipolar disorder therapeutics market: Pipeline portfolio
Exhibit 08: Global bipolar disorder therapeutics market 2014-2019 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of global bipolar disorder therapeutics market by drug class
Exhibit 11: Global bipolar disorder therapeutics market segment by geography 2014
Exhibit 12: Bipolar disorder therapeutics market revenue by geography 2014-2014 ($ millions)
Exhibit 13: Bipolar disorder therapeutics market in Americas 2014-2019 ($ millions)
Exhibit 14: Bipolar disorder therapeutics market in EMEA 2014-2019 ($ millions)
Exhibit 15: Bipolar disorder therapeutics market in APAC 2014-2019 ($ millions)
Exhibit 16: Impact of drivers
Exhibit 11: Common disorders that co-exist with bipolar disorder
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Market share analysis of global bipolar disorder therapeutics market 2014
Exhibit 19: YoY growth rate of major bipolar disorder drugs 2014-2019 ($ millions)
Exhibit 20: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Abilify 2011-2014 ($ millions)
Exhibit 21: Bristol-Myers Squibb: Percentage share of Abilify in US and non-US region based on revenue 2014
Exhibit 22: Bristol-Myers Squibb: Key takeaways
Exhibit 23: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel XR 2011-2014 ($ millions)
Exhibit 24: AstraZeneca: Revenue generated from sales of Seroquel XR by region 2014 ($ millions)
Exhibit 25: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel IR 2011-2014 ($ millions)
Exhibit 26: AstraZeneca: Key takeaways
Exhibit 27: Janssen Pharmaceuticals: YoY growth and revenue generated from net product sales of Risperdal Consta 2011-2014 ($ millions)
Exhibit 28: Janssen Pharmaceuticals: Key takeaways
Exhibit 29: Eli Lilly: YoY growth and revenue generated from net product sales of Zyprexa 2011-2014 ($ millions)
Exhibit 30: Eli Lilly: Key takeaways
Exhibit 31: GlaxoSmithKline: YoY growth and revenue generated from net product sales of Lamictal 2011-2014 ($ millions)
Exhibit 32: GlaxoSmithKline: Revenue generated from sales of Lamictal by region 2014 ($ millions)
Exhibit 33: GlaxoSmithKline: Key takeaways
Exhibit 34: Allergan: Key takeaways
Exhibit 35: Allergan: Business segmentation by product revenue 2014
Exhibit 36: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 37: Allergan: Geographical segmentation by revenue 2014
Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014
Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 41: BMS: Segmentation by revenue 2014
Exhibit 42: BMS: Segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 43: BMS: Geographical segmentation by revenue 2014
Exhibit 44: Lilly: Business segmentation by revenue 2014
Exhibit 45: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 46: Eli Lilly: Geographical segmentation by revenue 2014
Exhibit 47: GSK: Business segmentation by revenue 2014
Exhibit 48: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 49: GSK: Geographical segmentation by revenue 2014
Exhibit 50: Janssen Pharmaceuticals: Key therapeutic areas

Enquiry Before Buy